Getting the measure of the pressure: Optimal assessment of the effects of glucagon-like peptide-1 receptor agonists on blood pressure

Simple item page
dc.contributor.authorJones, K.L.
dc.contributor.authorMarathe, C.S.
dc.contributor.authorWu, T.
dc.contributor.authorRayner, C.K.
dc.contributor.authorNauck, M.
dc.contributor.authorHorowitz, M.
dc.date.issued2024
dc.description.statementofresponsibilityKaren L. Jones, Chinmay S. Marathe, Tongzhi Wu, Christopher K. Rayner, Michael Nauck, Michael Horowitz
dc.identifier.citationDiabetes, Obesity and Metabolism, 2024; 26(8):3003-3005
dc.identifier.doi10.1111/dom.15631
dc.identifier.issn1462-8902
dc.identifier.issn1463-1326
dc.identifier.orcidJones, K.L. [0000-0002-1155-5816]
dc.identifier.orcidWu, T. [0000-0003-1656-9210]
dc.identifier.orcidRayner, C.K. [0000-0002-5527-256X]
dc.identifier.orcidHorowitz, M. [0000-0002-0942-0306]
dc.identifier.urihttps://hdl.handle.net/2440/142587
dc.language.isoen
dc.publisherWiley
dc.relation.grantNHMRC
dc.rights© 2024 The Authors. Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
dc.source.urihttps://doi.org/10.1111/dom.15631
dc.subjectglucagon-like; blood pressure
dc.subject.meshHumans
dc.subject.meshHypertension
dc.subject.meshDiabetes Mellitus, Type 2
dc.subject.meshHypoglycemic Agents
dc.subject.meshBlood Pressure
dc.subject.meshGlucagon-Like Peptide-1 Receptor
dc.subject.meshGlucagon-Like Peptide-1 Receptor Agonists
dc.titleGetting the measure of the pressure: Optimal assessment of the effects of glucagon-like peptide-1 receptor agonists on blood pressure
dc.typeJournal article
pubs.publication-statusPublished

Files

Collections

Research Outputs